| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/22/2002 | EP1102581B1 A microemulsion forming composition for the sustained release of an active agent |
| 05/22/2002 | EP1089722B1 Matrix-type transdermal patch for steroid hormones |
| 05/22/2002 | EP1014940B1 Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
| 05/22/2002 | EP0902681B1 Inhibition of selectin binding |
| 05/22/2002 | EP0810822B1 Use of aerogels in agriculture |
| 05/22/2002 | EP0804501B1 Microcapsules containing a stabiliser mixture made from chromane derivatives, inert organic solvents and organic phosphites or phosphonites and/or amines. |
| 05/22/2002 | EP0797431B1 Aerosol formulations of peptides and proteins |
| 05/22/2002 | EP0792110B1 Silicone compositions |
| 05/22/2002 | EP0745085B1 Texaphyrin metal complexes having improved functionalization |
| 05/22/2002 | EP0726947B1 Insecticidal toxins derived from funnel web (atrax or hadronyche) spiders |
| 05/22/2002 | EP0650353B1 Palatable pharmaceutical compositions |
| 05/22/2002 | CN1350456A Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
| 05/22/2002 | CN1350454A Apomorphine and sildenafil composition |
| 05/22/2002 | CN1350450A Fast-dispersing dosage forms containing fish gelatin |
| 05/22/2002 | CN1350435A A composition containing carvacrol and thymol for use as abactericide |
| 05/22/2002 | CN1350009A Arylamine-o-quinone polymer and its prepn and use |
| 05/21/2002 | US6391886 Oral compositions having improved consumer aesthetics |
| 05/21/2002 | US6391879 Therapeutic anti-fungal nail preparation |
| 05/21/2002 | US6391870 Dopaminergic agent |
| 05/21/2002 | US6391857 Methods and compositions for endothelial binding |
| 05/21/2002 | US6391832 Medical emulsion for lubrication and delivery of drugs |
| 05/21/2002 | US6391565 Methods of detecting growth differentiation factor-3 |
| 05/21/2002 | US6391343 Particle comprising fibrinogen bound on surface of albumin matrix, capable of co-aggregation with platelets, and of aggregation in solution containing soluble fibrinogen at concentration not capable of clot formation by itself |
| 05/21/2002 | US6391340 Dry powder pharmaceutical formulation |
| 05/21/2002 | US6391336 Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| 05/21/2002 | US6391335 Effervescent drug delivery system for oral administration |
| 05/21/2002 | US6391303 Orally administering to animal pharmaceutical formulation comprising antigen and delivery agent comprising at least one derivatized amino acid or salt thereof in amount sufficient to induce tolerance to antigen |
| 05/21/2002 | US6391294 In situ formation of polymeric material |
| 05/21/2002 | CA2330480C Controlled release formulation of divalproex sodium |
| 05/21/2002 | CA2119932C Pressurized hydrofluoroalkane pharmaceutical aerosol compositions |
| 05/21/2002 | CA1341359C Manufacturing process for a single-cell lifeform killing or growth inhibiting composition containing fluorine (f-) and lithium (li+) |
| 05/20/2002 | WO2002039947A2 Carrier vectors through an epithelium with tight junctions |
| 05/17/2002 | CA2363147A1 Stable lactase compositions |
| 05/16/2002 | WO2002038775A2 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE |
| 05/16/2002 | WO2002038646A2 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters |
| 05/16/2002 | WO2002038609A2 Apolipoprotein conjugates |
| 05/16/2002 | WO2002038591A1 Fap-activated anti-tumor compounds |
| 05/16/2002 | WO2002038590A1 Fap-alpha-activated anti-tumor compounds |
| 05/16/2002 | WO2002038577A2 Extended release erythromycin derivatives |
| 05/16/2002 | WO2002038208A2 Device and method for the cessation of smoking |
| 05/16/2002 | WO2002038187A1 Fap-activated anti-tumour prodrug |
| 05/16/2002 | WO2002038186A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | WO2002038185A2 Injectable sustained release delivery system with loperamide |
| 05/16/2002 | WO2002038184A1 Oral pharmaceutical composition containing a block copolymer |
| 05/16/2002 | WO2002038171A2 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 05/16/2002 | WO2002038170A2 Stabilized inteferon compositions |
| 05/16/2002 | WO2002038168A2 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 05/16/2002 | WO2002038161A1 Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| 05/16/2002 | WO2002038154A1 Novel medicament compositions based on tiotropium salts and on salmeterol salts |
| 05/16/2002 | WO2002038139A1 Pharmaceutical preparation of percutaneous absorption type |
| 05/16/2002 | WO2002038133A2 Compositions containing hydrolytically unstable compounds |
| 05/16/2002 | WO2002038132A2 Soft capsules comprising a starch mixture having a reduced branching degree |
| 05/16/2002 | WO2002038129A2 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | WO2002038127A2 Particle formation methods and their products |
| 05/16/2002 | WO2002038123A1 A skin cream composition |
| 05/16/2002 | WO2002038105A2 Novel polyamine analog-amino acid conjugates useful as anticancer agents |
| 05/16/2002 | WO2002038077A2 L-histidine in ophthalmic solutions |
| 05/16/2002 | WO2002020026A3 Treatment of drug resistant organisms with nitric oxide |
| 05/16/2002 | WO2002018448A3 Percarboxylated polysaccharides, and a process for their preparation |
| 05/16/2002 | WO2002017892A3 Water-dispersible encapsulated sterols |
| 05/16/2002 | WO2002013762A3 Improved solid pharmaceutical dosage formulation of hydrophobic drugs |
| 05/16/2002 | WO2002009671A3 Microemulsion and micelle systems for solubilizing drugs |
| 05/16/2002 | WO2002007770A3 Polymeric conjugates of antitumor agents |
| 05/16/2002 | WO2001098364A3 Peptides, compositions and methods for the treatment of burkholderia cepacia |
| 05/16/2002 | WO2001097851A3 Compositions and methods to improve the oral absorption of antimicrobial agents |
| 05/16/2002 | WO2001091703A3 Low emulsifier multiple emulsions |
| 05/16/2002 | WO2001089514A3 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent |
| 05/16/2002 | WO2001088105A3 Production of dendritic cells from bone-marrow stem cells |
| 05/16/2002 | WO2001087289A3 Propofol for treatment of sepsis |
| 05/16/2002 | WO2001081405A3 Methods and compositions for the prevention and treatment of anemia |
| 05/16/2002 | WO2001076638A3 Compositions for drug delivery |
| 05/16/2002 | WO2001076597A3 A method of administering an antitumour compound using a polymer-camptothecin conjugate |
| 05/16/2002 | WO2001070663A3 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 05/16/2002 | WO2001068144A3 Biodegradable immunomodulatory formulations and methods for use thereof |
| 05/16/2002 | WO2001068143A3 Immunomodulatory formulations and methods for use thereof |
| 05/16/2002 | WO2001032125A3 Apparatus and process for preparing crystalline particles |
| 05/16/2002 | US20020058853 Method of administering a therapeutically active substance |
| 05/16/2002 | US20020058787 Mhc binding peptide oligomers and methods of use |
| 05/16/2002 | US20020058714 Base material for dry direct tableting comprising low-substituted hydroxypropyl cellulose |
| 05/16/2002 | US20020058695 Administering a bioavailability increasing effective amount of tetrahydropiperine, or an analog or derivative together with or proximate the administration of the nutrient or drug or other organic compound |
| 05/16/2002 | US20020058674 Used for therapy of conditions associated with mucosal surfaces such as cervical dysphasia and cervical intraepithelial neoplasia |
| 05/16/2002 | US20020058653 Administering cyclic polyamine compound to elevate white blood cell (WBC) count |
| 05/16/2002 | US20020058650 Penetration enhancing and irritation reducing systems |
| 05/16/2002 | US20020058647 Preparing a slurry of pamidronic acid in water, combining aqueous sodium hydroxide with slurry to obtain disodium pamidronate; packaging solution in sealed containers to obtain unit dosage |
| 05/16/2002 | US20020058634 Formulation of nitrogen mustard |
| 05/16/2002 | US20020058626 Increasing blood platelet formation by administering a parathyroid hormone or a derivative |
| 05/16/2002 | US20020058624 Powder containing physiologically active peptide |
| 05/16/2002 | US20020058616 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide) |
| 05/16/2002 | US20020058615 Endothelial specific targeting |
| 05/16/2002 | US20020058614 Especially administered by direct injection into the afflicted cartilagenous region or joint. |
| 05/16/2002 | US20020058611 Therapeutic agent is conjugated to the carrier via a biodegradable disulfide bond. |
| 05/16/2002 | US20020058608 Buffered drug formulations for transdermal electrotransport delivery |
| 05/16/2002 | US20020058601 Low-foaming; good biodegradability; can be used in polymer, antifoaming, biocidal, coating, fertilizer, pharmaceutical, and drilling fluid compositions. |
| 05/16/2002 | US20020058318 Gels for encapsulation of biological materials |
| 05/16/2002 | US20020058284 Methods and compositions for treating macrophage-mediated diseases |
| 05/16/2002 | US20020058097 Gelling agents and gels containing them |
| 05/16/2002 | US20020058069 Use of microparticles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration |
| 05/16/2002 | US20020058067 Solid drug delivery system |
| 05/16/2002 | US20020058066 Outer layer portion containing cilostazol, a water-insoluble substance, such as ethyl cellulose, and a hydrophilic hydrogel forming substance, such as hydroxypropyl methyl cellulose. |
| 05/16/2002 | US20020058065 Insoluble drug particle compositions with improved fasted-fed effects |